Tipranavir
- Generic Name
- Tipranavir
- Brand Names
- Aptivus
- Drug Type
- Small Molecule
- Chemical Formula
- C31H33F3N2O5S
- CAS Number
- 174484-41-4
- Unique Ingredient Identifier
- ZZT404XD09
- Background
Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. Tipranavir and ritonavir are coadministered to treat HIV.
- Indication
For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy Volunteers
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT02245451
Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 23
- Registration Number
- NCT02245269
Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT02244190
Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 29
- Registration Number
- NCT02226978
Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 34
- Registration Number
- NCT02226991
A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2014-03-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 42
- Registration Number
- NCT00976950
- Locations
- 🇷🇴
Boehringer Ingelheim Investigational site 17, Brasov, Romania
🇷🇴Boehringer Ingelheim Investigational site 2, Bucuresti, Romania
🇷🇴Boehringer Ingelheim Investigational site 20, Tg.Mures, Romania
An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.
- Conditions
- HIV Infections
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT00933205
- Locations
- 🇧🇪
1182.16.3202 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium
🇧🇪1182.16.3203 Boehringer Ingelheim Investigational Site, Brussel, Belgium
🇧🇪1182.16.3204 Boehringer Ingelheim Investigational Site, Gent, Belgium
Surveillance Cohort Long-term Toxicity Antiretrovirals in HIV-infected Patients Enrolled in TPV Cohort
- Conditions
- HIV Infections
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT00805857
Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy
- Conditions
- HIV Infections
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 42
- Registration Number
- NCT00615290
- Locations
- 🇫🇷
1182.127.3301 Boehringer Ingelheim Investigational Site, Strasbourg, France
🇫🇷Boehringer Ingelheim Investigational Site, Villeneuve St G, France
Optimizing Treatment for Treatment-Experienced, HIV-Infected People
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 517
- Registration Number
- NCT00537394
- Locations
- 🇺🇸
Children's National Med. Ctr. ATN CRS, Washington, District of Columbia, United States
🇺🇸Univ. of Rochester ACTG CRS, Rochester, New York, United States
🇺🇸UCLA CARE Center CRS, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.